The European Medicines Agency Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema

Takeda Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom

TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients.In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1View original content:https://www.prnewswire.co.uk/news-releases/the-european-medicines-agency-ema-has-approved-an-additional-subcutaneous-administration-option-for-takhzyro-lanadelumab-for-patients-aged-12-years-and-above-with-recurrent-attacks-of-hereditary-angioedema-hae-302382239.html